Komori
Kidswell Bio (4584) · PolicyAdvanced

Aligning interests with shareholders through stock-price-linked stock options

First written in FY2021. 7 of 8 entries say "Advanced", first in FY2022-Q2. Latest entry: 2026-08-25.

8entries
6years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2022-Q2 – 2026-08-252021: 220212022: 120222023: 120232024: 120242025: 120252026: 22026
Same theme, other companies
Grant and Issuance of Equity Compensation to Employees and Officers (Stock Options and Restricted Stock)A theme 654 companies write about · 0 as a headwind · 735 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 179 companies compared. The sentences above are computed from all 179.Comparing 200 of the theme's 737 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1AdvancedAnnual report

    「Resolution date 8 August 2025 Categories and number of grantees 4 Company directors 3 Company audit & supervisory board members Number of stock acquisition rights: 290 Resolution date 8 August 2025 Categories and number of grantees 29 Company employees Number of stock acquisition rights: 979」

    For stock options linked to the share price resolved on 8 August 2025, 290 options were granted to 4 directors and 3 audit & supervisory board members, and 979 options were granted to 29 employees.
  2. FY2025-H1AdvancedAnnual report

    「Resolution date 12 September 2024 Categories and number of grantees 4 Company directors 3 Company audit & supervisory board members Number of stock acquisition rights: 221」

    The Company disclosed the details of stock options linked to the share price that were resolved on 12 September 2024 and granted to 4 directors and 3 audit & supervisory board members, totaling 221 options. A further 892 options were granted to 37 employees.
  3. FY2024-Q2AdvancedAnnual report

    「Resolution date 8 September 2023 Categories and number of grantees 3 Company directors 3 Company audit & supervisory board members Number of stock acquisition rights: 110 Resolution date 8 September 2023 Categories and number of grantees 40 Company employees Number of stock acquisition rights: 1,118」

    The Company disclosed the details of stock options linked to the share price that were resolved on 8 September 2023 and granted to directors, audit & supervisory board members and employees. The total number of underlying shares was 122,800, with the exercise period running from 27 September 2026 to 26 September 2028 for officers and from 27 September 2025 to 26 September 2027 for employees.
  4. FY2023-Q2AdvancedAnnual report

    「Resolution date 9 September 2022 Categories and number of grantees 2 Company directors 3 Company audit & supervisory board members Number of stock acquisition rights: 57 Resolution date 9 September 2022 Categories and number of grantees 36 Company employees Number of stock acquisition rights: 724」

    The Company disclosed the details of stock options linked to the share price that were resolved on 9 September 2022 and granted to directors, audit & supervisory board members and employees.
  5. FY2022-Q2AdvancedAnnual report

    「Resolution date 10 September 2021 Categories and number of grantees 3 Company directors 3 Company audit & supervisory board members Number of stock acquisition rights: 71」

    The Company disclosed the details of the stock options resolved on 10 September 2021, under which 71 options were granted to 3 directors and 3 audit & supervisory board members based on the policy of sharing the benefits and risks of share-price fluctuations with shareholders. The grant of 807 options to 35 employees was also disclosed.
  6. FY2021First statedAnnual report

    「Stock options will be granted as non-monetary compensation to share with shareholders the benefits and risks of share-price fluctuations and strengthen incentives to improve business performance.」

    The Company explicitly stated its policy of granting stock options in addition to fixed compensation for directors and officers, thereby sharing with shareholders the benefits and risks of share-price fluctuations.
Moved together

"Enhancing Development Capabilities and Speed Through Partnerships with Contract Research Organizations and Pharmaceutical Companies" moved the same way as this thread, in the same document, in 4 of its 8 moves.

443222★123456
  1. ★This thread
  2. 1Enhancing Development Capabilities and Speed Through Partnerships with Contract Research Organizations and Pharmaceutical Companies4×
  3. 2MCB/WCB Manufacturing and Establishment of a Stable Supply System with Nikon Cell Innovation4×
  4. 3Four-party joint research on a treatment for cerebral palsy using dental pulp stem cells3×
  5. 4A Hybrid Business Model Building Stability through Biosimilars and Pursuing Growth through Novel Biologics2×
  6. 5Diversifying R&D Risk Through Multiple Products Under Development2×
  7. 6Early Profitability and Strengthening the Financial Condition2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Kidswell Bio yet. It last moved in the Share Issuance and Disposal of 2026-08-25: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Aligning interests with shareholders through stock-price-linked stock options | Kidswell Bio Corporation (4584) | Komori